Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells

Figures & data

Table 1. Inhibitory effects of rmhTRAIL on the proliferation of RPMI8226 and U266 cells.

Inhibitory rate (%)	Treatment times (h)	rmhTRAIL concentrations (ng ml^−1)
		15.625	62.5	250	1000
RPMI8226	24	6.96 ± 0.804	12.73 ± 2.42c	26.69 ± 3.56cd	30.02 ± 2.29cde
	48	12.89 ± 1.82a	36.29 ± 2.63ac	43.17 ± 3.43acd	52.14 ± 1.36acde
	72	27.80 ± 3.32ab	63.09 ± 1.73abc	73.60 ± 1.19abcd	77.91 ± 1.20abcde
U266	48	2.99 ± 2.87	8.47 ± 1.48c	14.33 ± 2.12cd	17.37 ± 1.51cde
	72	10.26 ± 0.34b	9.42 ± 0.93bc	20.72 ± 0.87bcd	26.56 ± 1.69bcde
	96	9.91 ± 0.50b	10.51 ± 1.29bc	19.67 ± 0.82bcd	25.86 ± 4.93bcde

Notes: a and b represent significant differences of p < 0.05 between 24 and 48 h, respectively. c, d, and e represent significant differences of p < 0.05 when compared with 62.5, 250, and 1000 ng ml⁻¹ rmhTRAIL, respectively.

Table 2. Inhibitory effects of 17-AAG on the proliferation of RPMI8226 and U266 cells following 72 h of treatment with different concentrations of 17-AAG.

RPMI8226 cells		U266 cells
Concentrations (ng ml^−1)	Inhibitory rate (%)	Concentrations (ng ml^−1)	Inhibitory rate (%)
312.5	8.49 ± 0.73a	78	9.48 ± 2.31a
625	19.12 ± 0.89b	156.25	14.31 ± 4.25b
1250	44.46 ± 9.48c	312.5	21.80 ± 2.13c
2500	65.91 ± 10.71d	625	54.01 ± 4.75d
5000	75.97 ± 9.47e	1250	88.70 ± 7.03e
10,000	81.96 ± 11.53f	2500	96.26 ± 1.97f

Note: Lowercase letters a, b, c, d, e, and f indicate significant differences of p < 0.05.

Table 3. Combination effects of rmhTRAIL and 17-AAG on the proliferation of RPMI8226 and U266 cells at 72 h post-treatment.

	rmhTRAIL (ng ml^−1)	17-AAG (ng ml^−1)	Inhibitory rate (%)	Q-value
RPMI8226	15.625	–	27.80 ± 3.32a	–
	–	312.5	8.49 ± 0.73b	–
	–	625	19.12 ± 0.8c	–
	15.625	312.5	47.38 ± 1.25d	1.77 ± 0.09
	15.625	625	53.08 ± 1.79e	1.24 ± 0.06
U266	1000	–	26.56 ± 1.69a	–
	–	312.5	21.80 ± 2.13b	–
	–	625	54.01 ± 4.75c	–
	1000	312.5	42.68 ± 2.17d	1.012 ± 0.10
	1000	625	72.09 ± 3.20e	1.056 ± 0.07

Note: Lowercase letters a, b, c, d, and e indicate significant differences of p < 0.05.

Figure 1. Combination effects of rmhTRAIL and 17-AAG on the apoptosis of RPMI8226 cells at 24 and 48 h post-treatment.

Figure 2. Combination effects of rmhTRAIL and 17-AAG on the apoptosis of U266 cells at 24 and 48 h post-treatment.